Contact: info@alspinc.com
“So we assembled a world-class team of researchers, including a world leader in Alzheimer’s from a Nobel-prize-winning lab, the best neurologists and neurosurgeons specialized in traumatic brain injury and top business professionals and intellectual property experts"



ALSP Inc. is led by a dedicated team of experienced executives, scientists and thought leaders that have extensive business and clinical experience in drug development.

 








“So we assembled a world-class team of researchers, including a world leader in Alzheimer’s from a Nobel-prize-winning lab, the best neurologists and neurosurgeons specialized in traumatic brain injury and top business professionals and intellectual property experts"

ALSP Inc. Management Team

 

Michael D.Pierschbacher, Ph.D.

President and Chief Executive Officer

Steven Jacobsen, Ph.D. 

Sr. Vice President and Chief Scientific Officer


Gregory Hook, Ph.D., J.D.

Co-Founder, Vice President, Alzheimer's Disease Research, and Corporate Counsel


Robert J. Ternansky, Ph.D.

Vice President, Medicinal Chemistry


Gregory P. Einhorn, Ph.D., J.D.

Vice President, Intellectual Property


< Back

 

ERIN S. ENRIGHT is the Chief Financial Officer of ALSP, Inc.  She is also a Managing Member of Prettybrook Partners, LLC, a private investment firm, and a general partner and member of the Board of Tigerlabs, a Princeton-based business accelerator. She served on the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL), and has served on the Board of Directors of Ceelite Technologies, LLC since 2010.  Ms. Enright was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004 to 2013. She served as Chief Financial Officer of InfuSystem, Inc. (NYSE: INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. 
While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. 
Steven Jacobsen, Ph.D.
Sr. VP and Chief Financial Officer

Steven Jacobsen, Ph.D. Former Senior Project Director, Translational Neurosciences, Neuroscience iMed, AstraZeneca.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Steven Jacobsen, Ph.D., was Former Senior Project Director at Translational Neurosciences, Neuroscience iMed, AstraZeneca
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
. Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. 

He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years. Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid. In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State University and New York University School of Medicine.

Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.


Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.

 
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.

Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.

Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.

Steven Jacobsen, Ph.D. Former Senior Project Director, Translational Neurosciences, Neuroscience iMed, AstraZeneca.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.
Steven Jacobsen, Ph.D. Former Senior Project Director, Translational Neurosciences, Neuroscience iMed, AstraZeneca.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School
Steven Jacobsen, Ph.D. Former Senior Project Director, Translational Neurosciences, Neuroscience iMed, AstraZeneca.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School
Steven Jacobsen, Ph.D. Former Senior Project Director, Translational Neurosciences, Neuroscience iMed, AstraZeneca.
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for three years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Associated Director/Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.
Dr. Jacobsen obtained his BS in Biology and a MS in Microbiology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from Graduate School of Biomedical Science, New Jersey Medical School.

While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. roup, most recently as a Managing Director in its Equity Capital Markets group.
 

While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. 

While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. 

While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. 
ERIN S. ENRIGHT is the Chief Financial Officer of ALSP, Inc.  She is also a Managing Member of Prettybrook Partners, LLC, a private investment firm, and a general partner and member of the Board of Tigerlabs, a Princeton-based business accelerator. She served on the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL), and has served on the Board of Directors of Ceelite Technologies, LLC since 2010.  Ms. Enright was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004 to 2013. She served as Chief Financial Officer of InfuSystem, Inc. (NYSE: INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. 
While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School. 
ERIN S. ENRIGHT is the Chief Financial Officer of ALSP, Inc.  She is also a Managing Member of Prettybrook Partners, LLC, a private investment firm, and a general partner and member of the Board of Tigerlabs, a Princeton-based business accelerator. She served on the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL), and has served on the Board of Directors of Ceelite Technologies, LLC since 2010.  Ms. Enright was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004 to 2013. She served as Chief Financial Officer of InfuSystem, Inc. (NYSE: INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. 
While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School.